172 related articles for article (PubMed ID: 15118072)
21. Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.
Sharma A; Tan TH; Cheetham G; Scott HS; Brown MP
J Thorac Oncol; 2012 May; 7(5):941-2. PubMed ID: 22722798
[No Abstract] [Full Text] [Related]
22. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Ji H; Li D; Chen L; Shimamura T; Kobayashi S; McNamara K; Mahmood U; Mitchell A; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Kim W; Jänne PA; Shapiro GI; Tenen D; Johnson BE; Weissleder R; Sharpless NE; Wong KK
Cancer Cell; 2006 Jun; 9(6):485-95. PubMed ID: 16730237
[TBL] [Abstract][Full Text] [Related]
23. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Reddy GK
Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
[No Abstract] [Full Text] [Related]
24. Medicine. Why a new cancer drug works well, in some patients.
Marx J
Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
[No Abstract] [Full Text] [Related]
25. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
26. Limitations of single-strand conformation polymorphism analysis as a high-throughput method for the detection of EGFR mutations in the clinical setting.
Weber F; Fukino K; Villalona-Calero M; Eng C
J Clin Oncol; 2005 Aug; 23(24):5847-8; author reply 5848-9. PubMed ID: 16110042
[No Abstract] [Full Text] [Related]
27. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
[No Abstract] [Full Text] [Related]
28. Molecular on/off switch.
Milton DT; Riely GJ; Pao W; Miller VA; Kris MG; Heelan RT
J Clin Oncol; 2006 Oct; 24(30):4940-2. PubMed ID: 17050880
[No Abstract] [Full Text] [Related]
29. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
Baselga J
J Clin Oncol; 2002 May; 20(9):2217-9. PubMed ID: 11980990
[No Abstract] [Full Text] [Related]
30. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
Arteaga CL
Cancer Cell; 2006 Jun; 9(6):421-3. PubMed ID: 16766261
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine kinase signal transduction inhibitors. Clinical trials.
Scagliotti GV
Suppl Tumori; 2002; 1(4):S34-6. PubMed ID: 12415814
[No Abstract] [Full Text] [Related]
32. EGFR mutations and sensitivity to gefitinib.
Sorscher SM
N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15371587
[No Abstract] [Full Text] [Related]
33. Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.
Pastorino U; Calabrò E; Tamborini E; Marchianò A; Orsenigo M; Fabbri A; Sozzi G; Novello S; De Marinis F
J Thorac Oncol; 2009 Feb; 4(2):266-7. PubMed ID: 19179908
[TBL] [Abstract][Full Text] [Related]
34. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
[TBL] [Abstract][Full Text] [Related]
35. The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.
Toyooka S; Date H; Uchida A; Kiura K; Takata M
Clin Cancer Res; 2007 Jun; 13(11):3431; author reply 3431-2. PubMed ID: 17545553
[No Abstract] [Full Text] [Related]
36. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
37. Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes.
Sterman DH
Chest; 2013 Mar; 143(3):597-600. PubMed ID: 23460149
[No Abstract] [Full Text] [Related]
38. Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib.
Schwab R; Pinter F; Moldavy J; Papay J; Strausz J; Kopper L; Keri G; Pap A; Petak I; Oreskovich K; Mangel L
J Clin Oncol; 2005 Oct; 23(30):7736-8. PubMed ID: 16234532
[No Abstract] [Full Text] [Related]
39. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
Alam N; Gustafson KS; Ladanyi M; Zakowski MF; Kapoor A; Truskinovsky AM; Dudek AZ
Clin Lung Cancer; 2010 Sep; 11(5):E1-4. PubMed ID: 20837450
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
Heuckmann JM; Rauh D; Thomas RK
J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
